Financial Management Professionals’s Neurocrine Biosciences NBIX Stock Holding History

Financial Management Professionals’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4	Closed	-$567	–	1010
2025 Q4	$567	Buy	+4	New	+$579	﹤0.01%	865
2024 Q4	–	Sell	-2	Closed	–	–	1023
2024 Q3	$0	Sell	2 -1	-33%	-$137	﹤0.01%	1001
2024 Q2	$0	Buy	3 +1	+50%	+$137	﹤0.01%	979
2024 Q1	$0	Hold	2	–	–	﹤0.01%	1033
2023 Q4	$0	Hold	2	–	–	﹤0.01%	1011
2023 Q3	$0	Buy	+2	New	+$211	﹤0.01%	991
2023 Q2	–	Sell	-34	Closed	-$3K	–	1045
2023 Q1	$3K	Buy	34 +31	+1,033%	+$3.23K	﹤0.01%	763
2022 Q4	$0	Buy	3 +1	+50%	+$117	﹤0.01%	1025
2022 Q3	$0	Sell	2 -10	-83%	-$1.01K	﹤0.01%	1045
2022 Q2	$1K	Sell	12 -10	-45%	-$923	﹤0.01%	856
2022 Q1	$2K	Buy	+22	New	+$1.86K	﹤0.01%	792

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Management Professionals's NBIX Position: Q1 2026 in Review

Financial Management Professionals sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 4 shares — an estimated $567 sold.

Financial Management Professionals first reported a position in NBIX in Q1 2022 and held it in 11 quarters. The position peaked at $3K in Q1 2023. 700 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Financial Management Professionals reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Financial Management Professionals sold 4 Neurocrine Biosciences shares in Q1 2026, an estimated $567.
Financial Management Professionals first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 11 quarters.
Financial Management Professionals's Neurocrine Biosciences position peaked at $3K in Q1 2023.
700 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Financial Management Professionals's 13F filing for Q1 2026, filed 15 Apr 2026.